‹ Back

Toggle Daily

FDA nominee Heidi Overton faces senators over her abortion pill views on Thursday

September 24, 2026

The Senate health committee questions Heidi Overton, whom Trump picked to run the FDA, on Thursday over her views on abortion and vaccines.

Trump picked Heidi Overton to run the Food and Drug Administration; she had been an America First Policy Institute executive whose papers criticized abortion and transgender care.

Key facts

Heidi Overton appears on Thursday before the Senate panel that covers health, education, labor and pensions as Trump's choice to run the Food and Drug Administration, AP News reports, and The Hill and Reuters give the same date and panel. Her abortion record draws the most attention in the AP News account. While she held an executive post at the America First Policy Institute, she attacked the agency's 2023 move, made under Joe Biden, that let mifepristone reach patients by mail, and she labeled it "chemical abortion on demand." PBS carries the same material.

The outlets agree on where the vote gets difficult. AP News reports that Senators Susan Collins of Maine and Lisa Murkowski of Alaska, Republicans who have broken with their party to back federal abortion access, sit on the panel, and that her abortion positions could make them harder to win. Collins, AP News adds, is fighting a close reelection race in which abortion is a central issue. The Hill treats the nomination as a test for Collins on abortion, while Reuters pairs questions about vaccines with those about the abortion pill. On vaccines, AP News reports that Overton was in the Oval Office last month beside Trump and Kennedy, the health secretary, when the two falsely linked combination vaccines to autism. Bill Cassidy, the Louisiana physician who chairs the committee, said her backing for a plan to stagger vaccinations came close to disqualifying her.

AP News also reports a 2024 article Overton co-wrote attacking Tim Walz, then Minnesota's governor, and her criticism of the administration's handling of transgender care for children. On her disclosure forms, she lists no holdings in food or health care companies and owes between $50,000 and $100,000 on student loans. Mifepristone has carried FDA approval since 2000, and the agency's officials have given little detail on its review beyond saying it continues. NBC News reports the nomination in light of the tenure of Marty Makary, who stepped down as FDA head. The outlets line up on her record and the hearing date; how the committee, Collins and Murkowski among them, responds is not yet known.

Still developing

The FDA review of mifepristone is ongoing. The stance of Senators Susan Collins of Maine and Lisa Murkowski of Alaska, moderate Republicans on the panel, on Overton's nomination is the question ahead of the hearing.

How settled the reporting is

Reported 100% · Contested 0% · Developing 0%

Sources

Toggle read the full reports of all 7 outlets counted on this event.